Category Archives: Biotechnology

Reportspedia recently added its expanding repository with a new research study. The research report, entitled Biotechnology and Pharmaceutical Services Outsourcing Market mainly includes a complete segmentation of this sector that is expected to generate massive returns by the end of the forecast period, showing a significant growth rate on an annual basis over the coming years. The research study also discusses the need for Biotechnology and Pharmaceutical Services Outsourcing Market explicitly.

Get Sample Report in PDF Version along with Graphs and [emailprotected]

https://www.reportspedia.com/report/business-services/global-biotechnology-and-pharmaceutical-services-outsourcing-market-report-2020-by-key-players,-types,-applications,-countries,-market-size,-forecast-to-2026-(based-on-2020-covid-19-worldwide-spread)/70872#request_sample

A detailed study of the competitive landscape of the Biotechnology and Pharmaceutical Services Outsourcing Industry Market has established, providing insights into the corporate profiles, latest developments, mergers, and acquisitions, and therefore the SWOT analysis. This breakdown report will offer a clear program to readers concerns regarding the overall market situation to further choose on this market project.

Key players profiled in the Biotechnology and Pharmaceutical Services Outsourcing Market report includes:

Quality ContextConcept Heidelberg GmbHParexel International CorporationQuintilesIMSManagement ForumGMP PharmaceuticalsInspired PharmaLachman AssociatesQuantic GroupRSSL

Ask For Discount:

https://www.reportspedia.com/discount_inquiry/discount/70872

Geographically, the Biotechnology and Pharmaceutical Services Outsourcing report includes the research on production, consumption, revenue, market share and growth rate, and forecast (2020-2026) of the following regions:

United States

Europe (Germany, UK, France, Italy, Spain, Russia, Poland)

China

Japan

India

Southeast Asia (Malaysia, Singapore, Philippines, Indonesia, Thailand, Vietnam)

Central and South America (Brazil, Mexico, Colombia)

Middle East and Africa (Saudi Arabia, United Arab Emirates, Turkey, Egypt, South Africa, Nigeria)

Other Regions

Inquire Before Buying:

https://www.reportspedia.com/report/business-services/global-biotechnology-and-pharmaceutical-services-outsourcing-market-report-2020-by-key-players,-types,-applications,-countries,-market-size,-forecast-to-2026-(based-on-2020-covid-19-worldwide-spread)/70872#inquiry_before_buying

The global Biotechnology and Pharmaceutical Services Outsourcing Market is expected to witness of massive growth in the next few years. The rising level of competition among the players and the increasing focus on the growth of new products are likely to offer promising growth during the forecast period. The research study on the global Biotechnology and Pharmaceutical Services Outsourcing Market deals with a complete overview, highlighting the key aspects that are projected to surge the growth of the market in the near future.

Biotechnology and Pharmaceutical Services Outsourcing Market Segmentation by Type:

ConsultingAuditing & AssessmentRegulatory AffairsProduct MaintenanceProduct Design & DevelopmentProduct Testing & ValidationTraining & EducationOthers

Biotechnology and Pharmaceutical Services Outsourcing Market Segmentation by Application:

Regenerative MedicineBiobankingDrug Discovery

What To Expect From The Report

Some Major TOC Points:

Chapter 1. Biotechnology and Pharmaceutical Services Outsourcing Market Report Overview

Chapter 2. Global Biotechnology and Pharmaceutical Services Outsourcing Growth Trends

Chapter 3. Biotechnology and Pharmaceutical Services Outsourcing Market Share by Key Players

Chapter 4. Breakdown Data by Type and Application

Chapter 5. Biotechnology and Pharmaceutical Services Outsourcing Market by End Users/Application

Chapter 6. COVID-19 Outbreak: Biotechnology and Pharmaceutical Services Outsourcing Industry Impact

Chapter 7. Opportunity Breakdown in Covid-19 Crisis

Chapter 9. Biotechnology and Pharmaceutical Services Outsourcing Market Driving Force

And Many More

Get Full Table Of Contents:

https://www.reportspedia.com/report/business-services/global-biotechnology-and-pharmaceutical-services-outsourcing-market-report-2020-by-key-players,-types,-applications,-countries,-market-size,-forecast-to-2026-(based-on-2020-covid-19-worldwide-spread)/70872#table_of_contents

Conclusively, this report is a one-stop reference point for the industrial stakeholders to get the Free Biotechnology and Pharmaceutical Services Outsourcing Market to forecast of till 2026 This report helps to know the predictable market size, market status, future development, growth opportunity, challenges, and growth drivers by analysing the historical overall data of the considered market segments.

Read the original here:
Biotechnology and Pharmaceutical Services Outsourcing Market 2020 Industry Size Analyzed by Business Opportunity, Growth Factors, Trends, Applications...

The global market for agricultural biotechnology reached $29.2 billion in 2016. This market should reach $32.1 billion in 2017 and $53.7 billion in 2022, with a compound annual growth rate (CAGR) of 10.8%.

Report Scope:

The study scope includes key agricultural biotechnology tools (i.e., next generation DNA sequencing, biochips, RNA interference, synthetic biology tools and genome editing tools); synthetic biology-enabled chemicals and biofuels; biotech seeds; and biologicals.

BCC analyzes these technologies and products to determine present and future market sizes, and forecasted growth from 2017 through 2022. The report also discusses industry strategic alliances, industry structures, competitive dynamics, patent status, and market driving forces.

Request For Report sample @ https://www.trendsmarketresearch.com/report/sample/11789

BCC provides in-depth coverage of the agricultural biotechnology industry structure, including genomics technology providers (e.g., genome editing, NGS, microarray companies); major seed companies; biotech traits companies; synthetic biology tools companies; companies developing plant feedstocks; and agricultural biologicals companies. It provides an in-depth analysis of major industry acquisitions and alliances during 2015 and 2016.

70 agricultural and biotechnology companies are profiled in this report.

Report Includes:

An overview of the global markets for agricultural biotechnology and related emerging technologies Analyses of global market trends, with data from 2015 and 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022 Segmentation of the markets by product type (microarrays, DNA sequencing, biochips, synthetic biology-enabled and transgenic seeds), by crop type, and by geography Information on growth driving forces, market applications, industry structure and competitive dynamics Analysis of key technologies and products to determine the present and future status of the market Profiles of major players in the industry

REASONS FOR DOING THE STUDY

Agriculture is a fundamental and strategic component for a country. As a result, agricultural technologies provide competitive geographic advantage and are highlydesirable. Biotechnologies address the pressing industry need for higher crop yields. Agricultural biotechnology is a key and growing component of the global agricultureindustry and is thus of interest to a wide audience.

Request For Report Discounts @ https://www.trendsmarketresearch.com/report/discount/11789

This report seeks to provide a qualitative and quantitative description of the agricultural biotechnology industry so that emerging market opportunities can be identified and exploited by the reader.

The report does this by examining the main product applications and markets, helping companies to prioritize product opportunities and strategic opportunities. The reporthighlights key market and industry trends, as well as quantifying the main market segments. The reader is thus able to better understand industry structure and changesoccurring in the industry.

Rapid changes in technology-intensive fields such as DNA sequencing, genome editing, and synthetic biology are driving new products and applications in agriculture. These developments create unique market opportunities. This report analyzes these trends and their impact on future markets for agricultural products.

Based on these market and technology dynamics, it is especially timely to examine the agricultural biotechnology industry.

SCOPE AND FORMAT

The study scope includes key agricultural biotechnology tools (i.e., next generation DNA sequencing, biochips, RNA interference, synthetic biology tools and genomeediting tools); synthetic biology-enabled chemicals and biofuels; biotech seeds; and biologicals.

BCC analyzes these technologies and products to determine present and future market sizes, and forecasted growth from 2017 through 2022. The report also discusses industry strategic alliances, industry structures, competitive dynamics, patent status, and market driving forces.

BCC provides in-depth coverage of the agricultural biotechnology industry structure, including genomics technology providers (e.g., genome editing, NGS, microarraycompanies); major seed companies; biotech traits companies; synthetic biology tools companies; companies developing plant feedstocks; and agricultural biologicalscompanies. It provides an in-depth analysis of major industry acquisitions and alliances during 2015 and 2016.

70 agricultural and biotechnology companies are profiled in this report.

More Info of Impact Covid19 @ https://www.trendsmarketresearch.com/report/covid-19-analysis/11789

Follow this link:
Agricultural Biotechnology Market Overview on Future Threats the COVID-19 - Scientect

SAN FRANCISCO, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that data from its VIR-2218 clinical program will be featured at the European Association for the Study of the Liver (EASL) Digital International Liver Congress from August 27-29, 2020. VIR-2218 is an investigational small interfering ribonucleic acid (siRNA) that mediates RNA interference (RNAi) for the potential treatment of chronic hepatitis B virus (HBV) infection and is the first investigational medicine from Virs partnership with Alnylam Pharmaceuticals, Inc. to enter clinical trials.

Among the accepted abstracts is an oral presentation of preliminary antiviral activity and safety results from an ongoing Phase 2 study of VIR-2218 in patients with chronic HBV on nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs), which are standard of care. The data demonstrate that two monthly doses of VIR-2218 resulted in substantial, dose-dependent and durable reductions in hepatitis B surface antigen (HBsAg), a marker of active hepatitis B infection. The data also suggests that the Enhanced Stabilization Chemistry-Plus (ESC+) incorporated into VIR-2218 may result in an improved hepatic safety profile. Additional abstracts include safety and pharmacokinetic data from a Phase 1 study of VIR-2218, as well as preclinical data.

Chronic HBV infection is a major public health condition impacting almost 300 million people worldwide, and innovative approaches that do not require lifelong treatment are needed to sustainably address the disease, said Phillip Pang, M.D., Ph.D., Chief Medical Officer of Vir. By suppressing HBV protein expression, VIR-2218 is not only a potent antiviral, but also may serve to remove antigenic inhibition of T and B cell activity directed against HBV, enabling immunologic control. The well-tolerated and substantial dose-dependent reduction in HBsAg demonstrated to date by VIR-2218 supports our belief that it has the potential to serve as the backbone of a finite treatment regimen aimed at providing a functional cure for HBV.

VIR-2218 Scientific Research Presented at EASL

Oral Presentation:

The following poster presentations will be available on demand:

Advancing Clinical Trials for HBV Therapies

Based on preliminary Phase 2 results, Vir initiated a Phase 2 trial of VIR-2218 administered in combination with pegylated interferon alpha-2a, an approved immunomodulatory agent. Initial clinical data are expected next year.

In May 2020, Vir initiated a Phase 1 clinical trial of VIR-3434, an HBV-neutralizing monoclonal antibody with the potential to also be a therapeutic T cell vaccine. Recently, the first chronic HBV patient was treated in the program, following the study design to progress from healthy volunteers to HBV patients in a staggered, parallel fashion.

A Phase 2 clinical trial of VIR-2218 in combination with VIR-3434 is expected in 2021.

About Hepatitis BApproximately 290million people globally are chronically infected with HBV and approximately 900,000 of them die from HBV-associated complications each year. There is a significant unmet medical need for more effective therapies that lead to life-long control of the virus after a finite duration of therapy, which is the definition of a functional cure. For a registrational trial to demonstrate a functional cure, the formal endpoint accepted by theU.S. Food and Drug Administration(FDA) is undetectable hepatitis B virus surface antigen (HBsAg), defined as less than 0.05 international units per milliliter, as well as HBV DNA less than the lower limit of quantification, in the blood six months after the end of therapy. Currently, a year-long course of pegylated interferon-alpha (PEG-IFN-) is the best available curative therapy. It has a low functional cure rate of approximately three to seven percent. Alternatively, suppressive therapy with nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) is commonly used, but patients often require a lifetime of therapy.

About VIR-2218VIR-2218 is a subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. VIR-2218 is the first asset in the companys collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.

About VIR-3434VIR-3434 is a subcutaneously administered HBV-neutralizing monoclonal antibody designed to block entry of all 10 genotypes of HBV into hepatocytes and also to reduce the level of virions and subviral particles in the blood. VIR-3434 has been engineered to have an extended half-life as well as to potentially function as a T cell vaccine against HBV in infected patients.

About Vir BiotechnologyVir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus and tuberculosis. For more information, please visitwww.vir.bio.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, potential, aim, believe and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Virs expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the potential benefits of VIR-2218, pegylated interferon-alpha, ESC+ technology and VIR-3434 (individually or in combination), the expected timing of commencement of clinical trials and availability of clinical data, our goals with respect to the prophylaxis and/or treatment of HBV, the criteria for a functional cure of HBV and the potential ability of our product candidates to demonstrate such criteria, the potential of ESC+ technology to enhance the safety and therapeutic index of VIR-2218 and other siRNAs, and the potential benefits of Virs collaboration with Alnylam Pharmaceuticals, Inc. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data or results observed during clinical trials, difficulties in obtaining regulatory approval, challenges in accessing manufacturing capacity, clinical site activation rates or clinical trial enrollment rates that are lower than expected, changes in expected or existing competition, delays in or disruptions to Virs business or clinical trials due to the COVID-19 pandemic, geopolitical changes or other external factors, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Virs filings with the U.S. Securities and Exchange Commission, including the section titled Risk Factors contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

See more here:
Vir Biotechnology Presents Data on VIR-2218 from Clinical Studies for the Treatment of Hepatitis B at the EASL Digital International Liver Congress -...

Unity Biotechnology suffers setback for lead drug candidate UBX0101

Unity Biotechnology Inc. (UBX) reported its 12-week data from Phase 2 clinical study in patients with painful osteoarthritis of the knee. The data did not show any statistically significant difference between any arm of UBX0101 and placebo at the 12-week endpoint for change from baseline. The change was measured using WOMAC-A which is a standard measurement of pain in osteoarthritis. The company has decided not to progress the drug candidate into pivotal studies. UNITY has also decided to focus on its ophthalmologic and neurologic disease programs in the near future.

The Phase 2 placebo-controlled, double-blind study enrolled 183 eligible patients. These patients were randomized and were administered placebo, 0.5 mg, 2.0 mg, or 4.0 mg of UBX0101 via a single intra-articular injection. The drug candidate was found to be well-tolerated at all dose levels. The adverse events were also in line with previously reported data. The data did not show any treatment-related serious Adverse Event. Only one patient had to discontinue on account of an unrelated cardiovascular event.

Unity plans to continue collecting data from the Phase 2 up to 24 week. It will also collect data from the ongoing Phase 1b high-dose, repeat-dose study. The data collection will likely be completed in the second half of 2020. Jamie Dananberg, M.D., chief medical officer of Unity:

While we are disappointed in the outcome of the 12-week results of the Phase 2 study of UBX0101, I would like to acknowledge our team's hard work and commitment to executing a robust study that has provided clear results."

However, the company stated that it remains positive about the potential of senescent cells towards managing ageing related ailments. Unity plans to advance its other product UBX1325 for retinal diseases. This drug candidate works by controlling Bcl-xL, a distinct senolytic target. The company also specified that its current cash, cash equivalents, and investments are sufficient to fund operations well into 2022.

Unity is testing UBC1967 for treating age-related ailments including age-related macular degeneration, diabetic macular edema, and proliferative diabetic retinopathy. It is a distinct senolytic small molecule inhibitors of specific members of the Bcl-2 family of apoptosis regulatory proteins. UBC1967 works on the same line as UBX1325. Both these compounds focus on proteins that are necessary for the survival of senescent cells.

The company is currently going through a transitional phase as it had a new CEO earlier this year. Anirvan Ghosh, the new person at the helm, earlier acted as Biogen's head of early R&D. He said:

While these are not the results we had hoped for, the evidence that senescent cells contribute to diseases of aging remains compelling, and we are excited to advance UBX1325 for retinal diseases, which inhibits Bcl-xL, a distinct senolytic target."

Unity mainly works on developing a new category of therapeutics to slow or reverse the ageing process. The company aims to do it by selectively eliminating or modulating senescent cells. Some of the main age-related diseases focused upon by the company are neurological diseases, pulmonary diseases, eye diseases, and osteoarthritis.

ChromaDex Corp. (CDXC) reported the results of a human trial of its Niagen in managing cardiovascular health. The study showed that Niagen (nicotinamide riboside) supplement was able to control signs of inflammation including inflammatory cytokines in vivo. The study was conducted in a small group of end-stage heart failure patients and was funded by NIH.

Another arm of the study was conducted ex vivo and showed elevated mitochondrial respiration. The data showed that the drug candidate was able to lower inflammatory factor expressions in peripheral blood mononuclear cells isolated from human subjects and treated with nicotinamide riboside.

The study carried out by the ChromaDex External Research Program, the patients with the most significant forms of heart failure (Stage D) were supplemented with NR. Their blood was analyzed to detect levels of pro-inflammatory signaling molecules. The analysis was done for the respiration rate of PBMCs in both in vivo and ex vivo models. PBMCs have been shown to play a major role in the inflammatory response leading to the decompensation and worsening of heart failure.

The pilot study showed that the daily NR supplementation for 5 to 9 days improved the respiratory rate of PBMCs while also optimizing the levels of pro-inflammatory cytokine gene expressions. Dr. Andrew Shao, ChromaDex Senior Vice President of Global Scientific & Regulatory Affairs said:

We look forward to seeing the results from additional ongoing clinical research to further our understanding of Niagen's impact on cardiovascular health."

ChromaDex is the exclusive licensee of Dr. Charles Brenner's patented NR. The company has already been granted more than 20 patents related to NR. It has published eleven human trials showing the safety and efficacy of ChromaDex. It has also gained government regulatory acceptance in the United States, the European Union, Australia, and Canada.

Vanda Pharmaceuticals Inc. (VNDA) reported that the interim analysis of its lead drug candidate tradipitant showed that it may quicken clinical improvement in SARS-CoV-2 (COVID-19) pneumonia. The finding was derived from a preliminary analysis of the first 60 patients enrolled in the ODYSSEY study.

ODYSSEY is an ongoing Phase III double-blind placebo-controlled trial. It aims to evaluate the efficacy and safety of tradipitant in treating neurogenic inflammation of the lung secondary to SARS-CoV-2 (COVID-19) infection. The study was commenced in April 2020. Mihael H. Polymeropoulos, M.D., President and CEO of Vanda said:

These results, albeit preliminary, are exciting, offering the promise of a significant contribution in the treatment of COVID-19 and the prospect of making tradipitant part of the standard of care in accelerating recovery for patients with COVID-19 pneumonia."

The data demonstrated that a 14-day tradipitant treatment accelerated clinical improvement by day 7 while the drug candidate also numerically improved median time to clinical improvement by day 28. Both the treatment arms showed similar overall rates of improvement and mortality.

The study is expected to involve 300 patients. This is the first study evaluating tradipitant for this condition. The interim analysis was carried out for the better assessment of efficacy and safety of tradipitant. The study used a 7-point scale for evaluating clinical status. The clinical improvement was defined as an improvement of minimum 2 points in the 7-point ordinal scale.

Tradipitant is an NK-1R antagonist and is currently undergoing clinical development for various conditions including atopic dermatitis, motion sickness, and gastroparesis. However, the FDA has put a partial clinical hold on clinical protocols of longer than 12 weeks duration. The company had licensed the drug candidate from Eli Lilly and Company (LLY).

Thanks for reading. At the Total Pharma Tracker, we do more than follow biotech news. Using our IOMachine, our team of analysts work to be ahead of the curve.

That means that when the catalyst comes that will make or break a stock, we've positioned ourselves for success. And we share that positioning and all the analysis behind it with our members.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The rest is here:
Unity Biotechnology Setback, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha

Lets have a look at the case of Unity Biotechnology, because this is a story that wont get so many headlines. Unity has been investigating a really interesting but high-risk idea. Its in the anti-aging field, so those two adjectives sort of apply by definition, and its the hypothesis that one of the problems is the accumulation of senescent cells. Those are old cells that are not yet dead, but not so alive, either theyve lost the ability to divide, and problem other abilities as well, but theyre still just hanging around. In fact, they seem to be doing worse than that senescent cells secrete various inflammation signals and other molecules that actually seem to impair the function (and even the survival) of the cells around them. Theyve been implicated in a whole list of degenerative diseases, and there have been several studies in animal models that show beneficial effects of outright elimination of such cells on overall health and even lifespan as a whole (see those last few links for references).

Their lead candidate is UBX0101, which is a small-molecule inhibitor of theMDM2/p53 interaction (Ive been unable to find a structure). Thats a protein-protein target that has received a lot of attention over the years, and compounds that affect it have been reported to disrupt the whole senescent-cell secretion phenotype. Its a complicated story compounds that inhibit the MDM2 interaction often do so by binding to p53 and stabilizing it. That also tends to mean activating it as well, because MDM2 is sort of the default braking system for p53, which is at the center of a great big gigantic web of cellular activity. Its involved in tumor suppression (by monitoring for DNA damage), the cell cycle itself, apoptosis (another option if the damage is too severe), and more, and it certainly seems to have a big role in the done-with-that-cell-cycle-business phenotype of senescent cells. As that last link will show, though, such MDM2 inhibitors were first characterized as caused normal cells to become senescent themselves, but closer examination seems to indicate that this was a reversible effect once you stopped dosing cells with the compounds, and that their effect on natural senescent cells was something else entirely.

So Unity had done a Phase I trial with their compound in patients with osteoarthritis of the knee, which showed that it was well tolerated and actually seemed to show the sort of biomarker response that youd want to see. Today they reported their Phase II data: nothing. No response at all versus placebo in any arm of the study. The compounds development has been halted, and Unitys stock has taken a dreadful beating this morning on the NASDAQ.

There are several things to take away from this. None of them are new, but we all could use to be reminded of them (and people outside the field definitely need to be!) First off, Phase I results are not Phase II results, because they are not designed to read out on efficacy. We all need to keep that in mind during these coronavirus days we simply *do not have* the most important results for all the vaccine candidates that are in the clinic now, and trying to read the Phase I tea leaves can only take you so far. There is no substitute for a well-designed Phase II study, and every new drug has got to pass through one before you can say anything real about its use in human disease. Its also worth remembering that Phase III results rarely look better than the Phase II ones if anything, Phase III tends to expose limitations while its confirming that the good parts of the Phase II work were actually valid (if in fact it does that second part at all!) This particular drug is obviously not going to get there, but keep that in mind next time something barely clears a Phase II and then goes on further.

Another take-away is that anti-aging work is really, really hard. Gegen den Tod ist kein Krautlein gewachsen, or if youd rather take that dose in Latinhexameter, contra vim mortis non crescit herba in hortis. In other words, there is no herb against death. (I came across that one not by poring over collections of Latin sayings, but by spending my youth reading science fiction stories). I continue to think that combating aging is a very exciting area for therapeutic intervention, with potential effects on both overall health and lifespan, but it is an area thats very likely to hand us a lot of unexpected reverses. Like this one.

There are a lot of places where things could have broken down. From the micro to the macro, they include: maybe this compound isnt the right one to affect MDM2/p53, but its still a valid target. Or maybe that particular interaction isnt a valid target for senescent cell therapy, for reasons yet to be worked out. Perhaps theres something about osteoarthritis itself that makes it a less attractive test bed for this approach. Or it could be that senescent cell therapy in humans is just not going to work at all. The only way to understand these things is to do more work, apply more brainpower, and spend a lot more money. The hard way, in other words.

Original post:
Unity Biotechnology and Senescent Cell Therapy | In the Pipeline - Science Magazine

Roche and Regeneron have signed an manufacturing and distribution agreement on Regenerons Phase II therapeutic antibody for the treatment of COVID-19.

Roche AG and Regeneron Therapeutics Inc said their collaboration is aimed at increasing the global supply of REGN-COV2, an experimental antibody combination (REGN10987+REGN10933) designed to prevent severe course of the COVID-19 syndrome, by at least three and a half times. While Regeneron will be responsible for distribution in the US, Roche will take responsibility for supply of the rest of the world with the antibody therapeutic, which is directed against two different sites of the viral spike protein.

REGN-COV2 is currently being studied in two Phase IIb clinical trials as a therapeutic given to infected, hospitalised patients with COVID-19 and in a Phase III trial for passive immunisation in household contacts of infected individuals. The goal of the Phase IIb trials is to evaluate if the cocktail two anti-S-protein antibodies can prevent the severe immunological host reaction follwing viral replication in some patients, the Phase III study aims at demonstrating that passive immunisation with REGN-COV2 can protect non-infected people for a certain time.

REGN-COV2 could be a critical line of defense against the COVID-19 pandemic, said Bill Anderson, Chief Executive Officer of Roche Pharmaceuticals. Were committing our manufacturing expertise and capacity, and our global distribution network to bring Regenerons potential antibody combination to as many people around the world as we possibly can.

Under the terms of the agreement, each company has committed to dedicate a certain manufacturing capacity to REGN-COV2 each year, and the collaborators have already begun the technology transfer process. Each company will bear its own distribution expenses in their designated territories. The collaborators will jointly fund and execute the ongoing Phase III prevention and Phase I healthy volunteers safety studies as well as additional global studies to evaluate further the potential for REGN-COV2 in treating or preventing COVID-19. Roche will be primarily responsible for securing regulatory approvals outside the U.S., following the initial European Medicines Agency (EMA) approval, and conducting any additional studies specifically required for approval by regulators outside the U.S.

The two potent, virus-neutralizing antibodies that form REGN-COV2 bind non-competitively to the critical receptor binding domain of the virus's spike protein, which diminishes the ability of mutant viruses to escape treatment and protects against spike variants that have arisen in the human population

Link:
COVID-19: Roche and Regeneron join forces - European Biotechnology News

This report studies theAgriculture Biotechnologymarketwith many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the completeAgriculture Biotechnology marketanalysis segmented by companies, region, type and applications in the report.

The following players are covered in this report:ADAMA Agricultural Solutions, Vilmorin, Bayer, Biocentury Transgene, Certis, DowDuPont, Eurofins, Evogene, Global Bio-chem Technology, Syngenta, KWS Saat, Marina Biotech, Monsanto

The final report will add the analysis of the Impact of Covid-19 in this report Agriculture Biotechnology industry.

Get a Free Sample Copy @https://www.reportsandmarkets.com/sample-request/global-agriculture-biotechnology-market-size-status-and-forecast-2019-2025

Agriculture BiotechnologyMarket in its database, which provides an expert and in-depth analysis of key business trends and future market development prospects, key drivers and restraints, profiles of major market players, segmentation and forecasting. A Agriculture Biotechnology Market provides an extensive view of size; trends and shape have been developed in this report to identify factors that will exhibit a significant impact in boosting the sales of Agriculture Biotechnology Market in the near future.

This report focuses on the global Agriculture Biotechnology status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Agriculture Biotechnology development inUnitedStates, Europe, China, Japan, Southeast Asia, India, and Central & South America.

Segment by Type

Segment by Application

TheAgriculture Biotechnologymarket is a comprehensive report which offers a meticulous overview of the market share, size, trends, demand, product analysis, application analysis, regional outlook, competitive strategies, forecasts, and strategies impacting the Agriculture Biotechnology Industry. The report includes a detailed analysis of the market competitive landscape, with the help of detailed business profiles, SWOT analysis, project feasibility analysis, and several other details about the key companies operating in the market.

The study objectives of this report are:

Inquire More about This Report @https://www.reportsandmarkets.com/enquiry/global-agriculture-biotechnology-market-size-status-and-forecast-2019-2025

TheAgriculture Biotechnologymarket research report completely covers the vital statistics of the capacity, production, value, cost/profit, supply/demand import/export, further divided by company and country, and by application/type for best possible updated data representation in the figures, tables, pie chart, and graphs. These data representations provide predictive data regarding the future estimations for convincing market growth. The detailed and comprehensive knowledge about our publishers makes us out of the box in case of market analysis.

Reasons for Buying this Report

Table of Contents

Chapter 1:GlobalAgriculture BiotechnologyMarket Overview

Chapter 2:Agriculture Biotechnology Market Data Analysis

Chapter 3:Agriculture Biotechnology Technical Data Analysis

Chapter 4:Agriculture Biotechnology Government Policy and News

Chapter 5:Global Agriculture Biotechnology Market Manufacturing Process and Cost Structure

Chapter 6:Agriculture Biotechnology Productions Supply Sales Demand Market Status and Forecast

Chapter 7:Agriculture Biotechnology Key Manufacturers

Chapter 8:Up and Down Stream Industry Analysis

Chapter 9:Marketing Strategy -Agriculture Biotechnology Analysis

Chapter 10:Agriculture Biotechnology Development Trend Analysis

Chapter 11:Global Agriculture Biotechnology Market New Project Investment Feasibility Analysis

About Us:

Reports and Marketsis not just another company in this domain but is a part of a veteran group calledAlgoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world. The database of the company is updated on a daily basis. Our database contains a variety of industry verticals that include: Food Beverage, Automotive, Chemicals and Energy, IT & Telecom, Consumer, Healthcare, and many more. Each and every report goes through the appropriate research methodology, Checked from the professionals and analysts.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Here is the original post:
2020 Agriculture Biotechnology Market Report by Market Status, By Forecast, By Company Profiles, By Types and Applications - The Daily Chronicle

Viking Therapeutics Inc (VKTX) is around the top of the Biotechnology industry according to InvestorsObserver. VKTX received an overall rating of 66, which means that it scores higher than 66 percent of all stocks. Viking Therapeutics Inc also achieved a score of 78 in the Biotechnology industry, putting it above 78 percent of Biotechnology stocks. Biotechnology is ranked 18 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 66 would rank higher than 66 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Viking Therapeutics Inc (VKTX) stock is trading at $7.73 as of 9:49 AM on Thursday, Aug 20, a decline of -$0.01, or -0.13% from the previous closing price of $7.74. The stock has traded between $7.65 and $7.75 so far today. Volume today is below average. So far 63,199 shares have traded compared to average volume of 1,126,694 shares.

To screen for more stocks like VKTX click here.

Go here to read the rest:
Is Viking Therapeutics Inc (VKTX) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Compugen Ltd. (CGEN) is around the top of the Biotechnology industry according to InvestorsObserver. CGEN received an overall rating of 69, which means that it scores higher than 69 percent of all stocks. Compugen Ltd. also achieved a score of 83 in the Biotechnology industry, putting it above 83 percent of Biotechnology stocks. Biotechnology is ranked 20 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Compugen Ltd. (CGEN) stock is trading at $19.36 as of 11:39 AM on Wednesday, Aug 19, an increase of $1.55, or 8.7% from the previous closing price of $17.81. The stock has traded between $17.83 and $19.46 so far today. Volume today is 1,171,509 compared to average volume of 1,311,529.

To see InvestorsObserver's Sentiment Score for Compugen Ltd. click here.

Originally posted here:
Where Does Compugen Ltd. (CGEN) Stock Fall in the Biotechnology Field? - InvestorsObserver

The 67 rating InvestorsObserver gives to Provention Bio Inc (PRVB) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 78 percent of stocks in the Biotechnology industry, PRVBs 67 overall rating means the stock scores better than 67 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Provention Bio Inc (PRVB) stock is trading at $14.11 as of 11:39 AM on Wednesday, Aug 19, a gain of $0.94, or 7.14% from the previous closing price of $13.17. The stock has traded between $13.22 and $14.17 so far today. Volume today is below average. So far 228,276 shares have traded compared to average volume of 733,500 shares.

To see the top 5 stocks in Biotechnology click here.

See more here:
Is Provention Bio Inc (PRVB) the Top Pick in the Biotechnology Industry? - InvestorsObserver